stockrow
Saturday 7 November 2026
Export ARDX’s income statement to Excel — free account
Ardelyx, Inc.
ARDX Healthcare Biotechnology
Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024.
- Revenue
- +15.7%
- EPS
- +27.5%
- Free cash flow
- +938.8%
- Total debt
- +24.8%
Quarter to September 2026, against a year earlier
2.86
0.13
−4.35%
Follow ARDX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 3 | 2 |
+8 more TTM periods Free account |
| (34.85%) | (38.61%) | (39.46%) | (36.21%) | ||
| (10.33%) | (10.68%) | (12.69%) | (13.14%) | ||
ROIC |
(17.21%) | (18.62%) | (20.50%) | (24.37%) | |
Return on Tangible Assets |
(17.60%) | (17.88%) | (21.17%) | (20.82%) | |
Average Days of Receivables |
72.84 | 81.24 | 70.70 | 64.38 | |
Free Cash Flow per Share |
(0.06) | (0.07) | (0.15) | (0.18) | |
Free Cash Flow |
(15.96) | (17.92) | (37.50) | (43.97) | |
Capital Expenditures |
(0.44) | (0.60) | (1.24) | (1.49) | |
| Other line items | |||||
Cash ROIC |
(2.27%) | (2.62%) | (6.35%) | (6.93%) | |
Accounts Receivable Turnover |
5.51 | 5.54 | 6.61 | 6.29 | |
Accounts Payable Turnover |
1.00 | 0.85 | 1.53 | 2.24 | |
Inventory Turnover |
1.05 | 1.06 | 1.38 | 2.03 | |
Average Days of Payables |
473.26 | 551.93 | 321.15 | 177.57 | |
Days of Inventory on Hand |
343.66 | 371.57 | 259.07 | 163.73 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.02 | |
Research and Development Expense of Revenue |
20.15% | 19.34% | 17.95% | 17.56% | |
Selling, General and Administrative Expense of Revenue |
82.02% | 82.89% | 83.31% | 82.79% | |
Share Based Compensation of Revenue |
12.18% | 12.12% | 11.93% | 12.02% | |
Interest Coverage |
(1.28) | (1.24) | (1.29) | (1.44) | |
Operating CF/Net income |
0.28 | 0.31 | 0.62 | 0.69 | |
Depreciation/Fixed assets |
1.95 | 1.88 | 1.68 | 1.40 | |
Capex/Depreciation |
(0.14) | (0.18) | (0.37) | (0.49) | |
Revenue per Share |
1.87 | 1.82 | 1.74 | 1.69 | |
Operating CF per Share |
(0.06) | (0.07) | (0.15) | (0.18) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026